Objective Many common diseases currently require that samples be sent to remote labs for diagnosis. This is costly and takes time, increasing patient anxiety and delaying the start of treatment. This project will make it feasible to carry out automatic, accurate diagnosis at the local doctor's office. This will be achieved using bio-marker mRNA detection. Compared to commonly used approaches, mRNA detection avoids false positive results and has a high sensitivity. It can currently be used to detect cancer and a range of respiratory diseases, to mention a few. New bio-markers are developed every day. The partners have already developed prototype technology which partly demonstrates a microsystem operation of the mRNA approach.The project will build on this, providing the innovation needed to transform a promising technology to an integrated system suitable for practical use at point-of-care:- Provide support for all stages: cell concentration, lysis, purification, sample collection, reagent mixing, amplification and detection.-Develop disposable polymer chips for use in the portable instrument, including technology for storing all needed reagents on these chips.-Develop reliable techniques for multi-channel parallel detection (crucial for recognising disease signatures).-Address factors such as reliability, usability and cost which are crucial to acceptance by health care professionals.System accuracy will be validated on the specific case of HPV (the virus causing cervical cancer), by comparing with macroscopic results and alternative methods used at laboratories. The consortium includes two research institutes and two industrial firms (both SMEs), who have extensive experience with mRNA techniques, and are motivated to commercialise results. They will be assisted by a hospital acting as end user, validating system usability and clinical accuracy. Fields of science natural sciencesbiological sciencesmicrobiologyvirologynatural scienceschemical sciencespolymer sciencesmedical and health scienceshealth sciencesinfectious diseasesRNA virusescoronavirusesmedical and health sciencesclinical medicineoncologycervical cancermedical and health scienceshealth sciencesinfectious diseasesDNA viruses Keywords Nanotechnology Programme(s) FP6-NMP - Nanotechnologies and nanosciences, knowledge-based multifunctional materials and new production processes and devices: thematic priority 3 under the 'Focusing and integrating community research' of the 'Integrating and strengthening the European Research Area' specific programme 2002-2006. Topic(s) NMP-2004-IST-NMP-2 - Bio-sensors for Diagnosis and Healthcare Call for proposal Data not available Funding Scheme STREP - Specific Targeted Research Project Coordinator STIFTELSEN SINTEF EU contribution No data Address Strindveien 4 7465 TRONDHEIM Norway See on map Total cost No data Participants (5) Sort alphabetically Sort by EU Contribution Expand all Collapse all ALBERT-LUDWIGS-UNIVERSITAET FREIBURG Germany EU contribution No data Address FAHNENBERGPLATZ 79085 FREIBURG See on map Total cost No data BIOFLUIDIX GMBH Germany EU contribution No data Address GEORGE-KOEHLER-ALLEE 106 79110 FREIBURG See on map Total cost No data INSTITUT FUER MIKROTECHNIK MAINZ GMBH Germany EU contribution No data Address CARL-ZEISS-STRASSE 18-20 55129 MAINZ See on map Total cost No data NORCHIP AS Norway EU contribution No data Address INDUSTRIEVEIEN 8 3490 KLOKKARSTUA See on map Total cost No data THE COOMBE WOMEN'S HOSPITAL Ireland EU contribution No data Address DOLPHINS BARN ROAD - CORK STREET DUBLIN 8 See on map Total cost No data